Close

Dominick Arena Joins Implandata Ophthalmic Products GmbH Board of Directors as Chairman

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Eli Lilly’s $3.5 Billion Manufacturing Campus Advances in Upper Macungie, Pennsylvania

A planned $3.5 billion pharmaceutical manufacturing campus in Upper...

Overcoming Resistance-Associated Substitutions (RASs) to Direct-Acting Antivirals

Alt tag: Scientific illustration of Hepatitis C virus interacting...

Genentech Completes Structural Framework at New NC Manufacturing Facility

Genentech raised the final beam of its new Holly...
- Advertisement -

Implandata Ophthalmic Products GmbH is pleased to announce that Dominick Arena is appointed as its Chairman of the Board effective immediately.

Dominick is currently an Executive Advisor for Water Street Healthcare Partners, a strategic investor focused exclusively on the healthcare industry. He brings more than 30 years experience in the medical device industry.

Max Ostermeier, CEO of Implandata states: “The entire management team is extremely pleased that Dominick is joining our Board as Chairman. We look forward to closely working with him as we enter into a new and exciting phase with Implandata.  Dominick’s operational and commercial experience will be of tremendous help as we begin the commercialization of our products. Further his M&A background will play a key role as we position the company for future strategic partnerships.”

About Implandata
Implandata is a privately held, ISO 13485 certified medical device company, which was founded in 2010 in Hannover/Germany. Implandata is a leader in the development of monitoring technologies for the treatment of Glaucoma. With the CE marked EYEMATE system, Implandata has developed the world-wide first solution for continual monitoring of intraocular pressure.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

Eli Lilly’s $3.5 Billion Manufacturing Campus Advances in Upper Macungie, Pennsylvania

A planned $3.5 billion pharmaceutical manufacturing campus in Upper...

Overcoming Resistance-Associated Substitutions (RASs) to Direct-Acting Antivirals

Alt tag: Scientific illustration of Hepatitis C virus interacting...

Genentech Completes Structural Framework at New NC Manufacturing Facility

Genentech raised the final beam of its new Holly...

Chugai Pharmaceutical and GSK Sign Exclusive License Agreement for Anti-Dengue Antibody AID351

Japan-based Chugai Pharmaceutical has entered into an exclusive license...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »